I am a
Home I AM A Search Login

Papers of the Week

2020 May 25

Semin Arthritis Rheum



Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review.


Betrains A, Staels F, Vanderschueren S
Semin Arthritis Rheum. 2020 May 25; 50(4):636-642.
PMID: 32502728.


Schnitzler syndrome is a rare autoinflammatory disorder characterized by chronic urticarial rash and a monoclonal gammopathy, accompanied by intermittent fever, bone pain, and arthralgia or arthritis. Canakinumab is a fully human monoclonal anti-interleukin-1β (IL-1β) antibody proven to be effective in IL-1 driven autoinflammatory disorders.